Pharion Speciality Medicines

ZUNITRA ZOLEDRONIC ACID 4 MG INJ is an intravenous bisphosphonate used to treat osteoporosis, Paget’s disease, and bone complications from cancers. It helps strengthen bones, reduce fracture risk, and manage hypercalcemia by inhibiting bone resorption effectively.

NETOCTALAR 30 MG is a long-acting somatostatin analog used to treat acromegaly, neuroendocrine tumors, and hormone-related symptoms. It helps control excessive hormone secretion, reduces tumor-related complications, and improves overall patient well-being.

• Brand Name: Xpreza 100 mg

• Manufacture: Natco Pharma Ltd.

• Generic Name: Azacitidine

• Strength: 100 mg

• Dosage Form: Lyophilized Powder for Injection (for SC or IV use)

• Therapeutic Class: Antineoplastic agent, Hypomethylating agent

• Treatment of patients with myelodysplastic syndromes (MDS) including all French-American-British (FAB) subtypes (RA, RARS, RAEB, RAEB-T, CMML).

• Treatment of acute myeloid leukemia (AML) with 20–30% blasts and multi-lineage dysplasia, in adults not candidates for hematopoietic stem cell transplantation.

• Treatment of chronic myelomonocytic leukemia (CMML).

Azacitidine is a nucleoside metabolic inhibitor. It incorporates into DNA and RNA, causing hypomethylation of DNA and direct cytotoxicity to abnormal hematopoietic cells in bone marrow. DNA hypomethylation restores normal function of tumor suppressor genes, leading to differentiation or apoptosis of malignant cells.

• Recommended dose: 75 mg/m² daily for 7 days, administered by subcutaneous injection or intravenous infusion, repeated every 28 days.

• Treatment should be continued for a minimum of 4–6 cycles to assess response.

• Dose modification may be required for hematologic or renal toxicity.

• Reconstitution: Each vial should be reconstituted with sterile water for injection; prepared suspension/solution should be used immediately as per guidelines.

• Single-use vial containing 100 mg lyophilized powder.

• Supplied in cartons with prescribing information.

• Store at 2°C–8°C (refrigerated).

• Protect from light.

• Do not freeze.

• Use reconstituted solution immediately or within recommended stability period under refrigerated conditions.

• Hematologic Toxicity: Neutropenia, anemia, and thrombocytopenia are common; monitor complete blood counts before each cycle.

• Renal Toxicity: Use with caution in patients with renal impairment; monitor renal function.

• Hepatic Impairment: Limited data; caution advised in patients with hepatic dysfunction.

• Infections: Patients are at increased risk of infections; prompt management is essential.

• Gastrointestinal Effects: Nausea, vomiting, constipation, and diarrhea may occur; antiemetic prophylaxis may be considered.

• Injection Site Reactions: Pain, erythema, or swelling are common after SC administration.

• Pregnancy & Lactation: Contraindicated; may cause fetal harm. Breastfeeding should be avoided during therapy.

• Drug Interactions: No significant CYP-mediated drug interactions; however, caution is advised with concomitant myelosuppressive drugs.

• Elderly Patients: Most patients treated are older adults; careful monitoring required.

• Brand Name: Bortenat

• Generic Name: Bortezomib

• Strength: 3.5 mg per vial (as lyophilized powder)

• Dosage Form: Injectable powder for reconstitution

• Route of Administration: Intravenous (IV) or Subcutaneous (SC)

• Therapeutic Category: Anticancer / Proteasome Inhibitor

• Indications:

  • Multiple Myeloma (newly diagnosed, relapsed, or refractory)

  • Mantle Cell Lymphoma

• Mechanism of Action:

  • Inhibits the 26S proteasome, leading to disruption of protein degradation and cancer cell apoptosis

• Dosage & Administration:

  • Dose based on body surface area

  • Administered by qualified oncology professionals only

• Packaging: Single-use vial in sterile packaging

• Storage Conditions:

  • Store below 25°C

  • Protect from direct light and moisture

  • Use reconstituted solution within recommended time

• Precautions:

  • Cytotoxic agent – handle with care

  • For hospital or oncology clinic use only

  • Not for self-administration

• Regulatory Status: Prescription-only (Rx)

• Brand Name: Bortenat 2 mg

• Manufacture: Natco Pharma Ltd.

• Generic Name: Bortezomib

• Strength: 2 mg

• Dosage Form: Lyophilized Powder for Injection

• Therapeutic Class: Antineoplastic agent, Proteasome Inhibitor

• Treatment of patients with multiple myeloma.

• Treatment of patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.

Bortezomib is a reversible proteasome inhibitor. It specifically inhibits the 26S proteasome, a large protein complex responsible for degrading ubiquitinated proteins. Inhibition disrupts multiple signaling pathways, leading to cell cycle arrest and apoptosis of cancer cells, particularly malignant plasma cells in multiple myeloma.

• Recommended starting dose: 1.3 mg/m² administered as an intravenous (IV) bolus injection or subcutaneous (SC) injection twice weekly on days 1, 4, 8, and 11 of a 21-day treatment cycle.

• At least 72 hours gap should be maintained between consecutive doses.

• Dose adjustments may be required based on patient response, hematologic counts, and adverse events.

• Reconstitution: Each vial containing 2 mg bortezomib should be reconstituted with 0.9% Sodium Chloride Injection. Use immediately after preparation.

• Single-use vial containing 2 mg of lyophilized powder for injection.

• Supplied in cartons with instructions for use.

• Store at 2°C–8°C (Refrigerated).

• Protect from light.

• Do not freeze.

• Use reconstituted solution immediately; if not, store under refrigeration and use within specified time as per guidelines.

• Hematologic Toxicity: Risk of thrombocytopenia, neutropenia, and anemia; monitor blood counts before each dose.

• Peripheral Neuropathy: Common; dose adjustment or discontinuation may be required.

• Cardiac Toxicity: May cause heart failure, QT prolongation, and hypotension; monitor cardiac function.

• Hepatic Impairment: Use with caution; dose adjustments may be needed.

• Infections: Risk of viral reactivation (e.g., herpes zoster); prophylaxis may be considered.

• Pulmonary Toxicity: Rare cases of interstitial lung disease; discontinue if suspected.

• Pregnancy & Lactation: Contraindicated; can cause fetal harm. Avoid breastfeeding.

• Drug Interactions: Use cautiously with CYP3A4 inhibitors/inducers. Concomitant hypotensive agents may enhance risk of low blood pressure.

• Elderly Patients: More prone to adverse reactions; close monitoring recommended.V

BORVIN 2 Injection contains Bortezomib 2mg, a proteasome inhibitor used in the treatment of multiple myeloma and mantle cell lymphoma. It works by blocking cancer cell growth and inducing apoptosis. For intravenous or subcutaneous use under medical supervision only.

• Brand Name: Zoldonat

• Manufacture: Natco Pharma Ltd.

• Generic Name: Zoledronic Acid

• Strength: 4 mg/5 ml (single-dose vial)

• Dosage Form: Injection (IV infusion concentrate)

• Therapeutic Class: Bisphosphonate, Antiresorptive Agent

• Hypercalcemia of Malignancy (HCM).

• Bone Metastases: Reduction of skeletal-related events (fractures, spinal cord compression, bone pain) in patients with advanced malignancies involving bone (e.g., breast cancer, prostate cancer, multiple myeloma).

• Multiple Myeloma: Management of bone complications.

• Osteoporosis (off-label in oncology setting): Postmenopausal, glucocorticoid-induced, or male osteoporosis (where applicable).

Zoledronic acid is a nitrogen-containing bisphosphonate.

• Inhibits osteoclast-mediated bone resorption.

• Binds to bone mineral matrix and reduces bone turnover.

• Prevents skeletal complications associated with tumors and metastases.

• Also reduces serum calcium by decreasing osteoclastic activity.

• Hypercalcemia of Malignancy (HCM): 4 mg IV as a single dose, infused over ≥15 minutes.

• Multiple Myeloma and Bone Metastases: 4 mg IV every 3–4 weeks.

• Renal Impairment: Dose adjustments required (based on creatinine clearance). Contraindicated in severe renal impairment (CrCl <30 mL/min).

• Patients should be adequately hydrated prior to infusion.

• Supplementation with calcium and vitamin D is usually recommended.

• Must not be administered as a bolus injection.

• Supplied in vials containing 4 mg/5 ml concentrate for infusion.

• Pack size: Single vial per carton.

• Store below 30°C.

• Do not freeze.

• Diluted solution should be used immediately or within recommended stability limits.

• Keep out of reach of children.

• Renal Toxicity: Monitor serum creatinine before each dose; adjust or withhold in renal impairment.

• Hypocalcemia: Correct before initiating therapy; monitor calcium, phosphate, and magnesium during treatment.

• Osteonecrosis of the Jaw (ONJ): Reported with bisphosphonates; ensure dental evaluation before starting therapy.

• Bone, Joint, and Muscle Pain: Severe musculoskeletal pain may occur.

• Atrial Fibrillation: Increased incidence in some studies; monitor patients with cardiac risk.

• Hydration: Avoid overhydration in patients at risk of cardiac failure.

• Drug Interactions: Use cautiously with nephrotoxic drugs (e.g., aminoglycosides, NSAIDs).

• Pregnancy & Lactation: Contraindicated; potential fetal harm.

• Monitoring: Renal function, electrolytes, calcium, phosphate, magnesium, hematology as clinically indicated.

NETOCTALAR 20 MG is a potent synthetic somatostatin analog used to manage acromegaly, neuroendocrine tumors, and severe diarrhea associated with certain cancers. It helps control hormone overproduction, alleviating symptoms and improving patient quality of life.

SEGARELIX 120 MG is a GnRH receptor antagonist used for advanced prostate cancer. It rapidly lowers testosterone levels, helping control disease progression, reduce tumor growth, and manage symptoms effectively, offering a convenient alternative to traditional hormone therapies.

PEMAXAM INJ 500 MG is a chemotherapy agent used for treating advanced non-small cell lung cancer and malignant pleural mesothelioma. It inhibits folate-dependent enzymes, slowing cancer cell growth, reducing tumor progression, and supporting improved patient outcomes.

PEMAXAM INJ 100 MG is a chemotherapy medication used to treat various cancers, including non-small cell lung cancer and mesothelioma. It works by inhibiting folate-dependent enzymes, slowing cancer cell growth and helping improve patient outcomes.

Lifogem 200mg is a chemotherapy drug used in pancreatic, lung, breast, and bladder cancers. It inhibits cancer cell DNA replication, slowing tumor growth. Administered intravenously under medical supervision, it supports effective and targeted cancer treatment.

Lifogem 1g is a chemotherapy medicine used to treat pancreatic, lung, breast, and bladder cancers. It works by interfering with DNA replication in cancer cells, slowing tumor growth. Administered intravenously under medical supervision to ensure safe and effective therapy.

Leucorin Injection 2ml is used alongside chemotherapy to enhance treatment efficacy and reduce side effects. It helps protect healthy cells from certain chemotherapy drugs while boosting their cancer-killing effects. Administered intravenously under medical supervision.

Docet Docetaxel Injection 120mg is a chemotherapy medicine used to treat breast, lung, prostate, stomach, and head & neck cancers. It works by inhibiting cell division and stopping cancer cell growth. Administered intravenously under medical supervision, it helps improve treatment outcomes.

Leucorin 5ml is used with chemotherapy to improve effectiveness and reduce toxicity. It protects healthy cells from certain chemotherapy drugs while enhancing their cancer-fighting effects. Administered intravenously under medical supervision for safe treatment.

PEMNAT 500 contains Pemetrexed, an antifolate antineoplastic agent indicated for the treatment of non-small cell lung cancer and malignant pleural mesothelioma. It blocks folate-dependent enzymes required for DNA and RNA synthesis, thereby slowing the growth of cancer cells. Given as an intravenous infusion under medical supervision, it is commonly used alone or in combination with other chemotherapy drugs for effective cancer management.

PEMNAT 100 contains Pemetrexed, an antifolate chemotherapy agent used in the treatment of non-small cell lung cancer and malignant pleural mesothelioma. It works by inhibiting folate-dependent enzymes essential for DNA synthesis and cell replication, thereby slowing cancer cell growth. Administered as an intravenous infusion under strict medical supervision, it is often combined with other anticancer agents for effective treatment.

NETOCTALAR 20 MG is a potent synthetic somatostatin analog used to manage acromegaly, neuroendocrine tumors, and severe diarrhea associated with certain cancers. It helps control hormone overproduction, alleviating symptoms and improving patient quality of life.

Bevetas Bevacizumab Injection 100 mg is a monoclonal antibody used in the treatment of various cancers. It works by inhibiting vascular endothelial growth factor (VEGF), thereby restricting tumor blood supply and slowing disease progression. It is administered intravenously under medical supervision as part of prescribed oncology therapy.

Bevetas Bevacizumab Injection 400 mg is a monoclonal antibody used in the treatment of various solid tumors. It works by inhibiting vascular endothelial growth factor (VEGF), thereby preventing the formation of new blood vessels that support tumor growth. This helps slow disease progression and improve treatment outcomes. It is administered intravenously under strict medical supervision as part of oncology therapy.

Mabtas Rituximab Injection 500 mg is a monoclonal antibody used in the treatment of certain cancers and autoimmune disorders. It works by targeting CD20-positive B cells, helping to control abnormal cell growth and immune activity. Administered intravenously, it should be used under strict medical supervision as part of a prescribed treatment regimen.